Aliski William 4
4 · Ultragenyx Pharmaceutical Inc. · Filed Feb 23, 2021
Insider Transaction Report
Form 4
Aliski William
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-19$97.85/sh+7,500$733,875→ 73,204 total - Gift
Common Stock
2021-02-23−1,000→ 64,704 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-02-19−7,500→ 0 totalExercise: $97.85Exp: 2025-06-18→ Common Stock (7,500 underlying) - Sale
Common Stock
2021-02-19$149.01/sh−7,500$1,117,575→ 65,704 total
Holdings
- 10,456(indirect: By Trust)
Common Stock
- 70,350(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.00 to $149.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F3]These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust.
- [F4]These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts.
- [F5]The option vested in full on on June 9, 2016.